Evidence map›Paper›PMID 34787581›Full record

ArticleJMIR formative research2021

A Two-Minute Walking Test With a Smartphone App for Persons With Multiple Sclerosis: Validation Study.

Pim van Oirschot, Marco Heerings, Karine Wendrich, Bram den Teuling, Frank Dorssers, René van Ee, Marijn Bart Martens, Peter Joseph Jongen

Abstract read
In one paragraph

Article in JMIR formative research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pim van Oirschot *Orikami Digital Health Products, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0003-1135-0500
Marco HeeringsDutch National Multiple Sclerosis Foundation, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-9914-042X
Karine WendrichFaculty of Science, Institute for Science in Society, Radboud University, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-9413-1674
Bram den TeulingOrikami Digital Health Products, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-9084-5645
Frank DorssersOrikami Digital Health Products, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-9908-6665
René van EeOrikami Digital Health Products, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0002-6843-0133
Marijn Bart MartensDrug Target ID, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0002-5196-5131
Peter Joseph JongenDepartment of Community & Occupational Medicine, University Medical Centre Groningen, Groningen, Netherlands.ORCID https://orcid.org/0000-0002-9202-6309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWalking disturbances are a common dysfunction in persons with multiple sclerosis (MS). The 2-Minute Walking Test (2MWT) is widely used to quantify walking speed. We implemented a smartphone-based 2MWT (s2MWT) in MS sherpa, an app for persons with MS. When performing the s2MWT, users of the app are instructed to walk as fast as safely possible for 2 minutes in the open air, while the app records their movement and calculates the distance walked.

objectiveThe aim of this study is to investigate the concurrent validity and test-retest reliability of the MS sherpa s2MWT.

methodsWe performed a validation study on 25 persons with relapsing-remitting MS and 79 healthy control (HC) participants. In the HC group, 21 participants were matched to the persons with MS based on age, gender, and education and these followed the same assessment schedule as the persons with MS (the HC-matched group), whereas 58 participants had a less intense assessment schedule to determine reference values (the HC-normative group). Intraclass correlation coefficients (ICCs) were determined between the distance measured by the s2MWT and the distance measured using distance markers on the pavement during these s2MWT assessments. ICCs were also determined for test-retest reliability and derived from 10 smartphone tests per study participant, with 3 days in between each test. We interviewed 7 study participants with MS regarding their experiences with the s2MWT.

resultsIn total, 755 s2MWTs were completed. The adherence rate for the persons with MS and the participants in the HC-matched group was 92.4% (425/460). The calculated distance walked on the s2MWT was, on average, 8.43 m or 5% (SD 18.9 m or 11%) higher than the distance measured using distance markers (n=43). An ICC of 0.817 was found for the concurrent validity of the s2MWT in the combined analysis of persons with MS and HC participants. Average ICCs of 9 test-retest reliability analyses of the s2MWT for persons with MS and the participants in the HC-matched group were 0.648 (SD 0.150) and 0.600 (SD 0.090), respectively, whereas the average ICC of 2 test-retest reliability analyses of the s2MWT for the participants in the HC-normative group was 0.700 (SD 0.029). The interviewed study participants found the s2MWT easy to perform, but they also expressed that the test results can be confronting and that a pressure to reach a certain distance can be experienced.

conclusionsThe high correlation between s2MWT distance and the conventional 2MWT distance indicates a good concurrent validity. Similarly, high correlations underpin a good test-retest reliability of the s2MWT. We conclude that the s2MWT can be used to measure the distance that the persons with MS walk in 2 minutes outdoors near their home, from which both clinical studies and clinical practice can benefit.

Indexed as

2-Minute Walking Testmobile phonemobilitymultiple sclerosisrelapsing remitting

Identifiers

PMID34787581
PMCPMC8663688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.